Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of RB0026 for prevention of RSV infection in preterm and term infants in China
CTR20243661Phase 3Completed
- Sponsor
- Reyoung (Suzhou) Biotechnology
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of RB0026 in respiratory syncytial virus disease (RSV), sponsored by Reyoung (Suzhou) Biotechnology. Started Oct 2024; status: completed.
02
Drugs
RB0026
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20243661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243661.